The aim of this study is to evaluate oxidative stress in diabetes mellitus (DM) Type1 by the measurement of Glucose-6-phosphate Dehydrogenase (G-6-PD), an enzyme expressed in human RBCs, is important in the generation of reduced glutathione which is the key product in oxidative stress controls. The Study was carried on 80 samples of blood and serum of National Diabetes Center (NDC). The study groups under fasting conditions and they divided as:20 samples of diabetes mellitus patients without complications and 20 samples of diabetes mellitus with cardiovascular (CV) complications and 20 samples of diabetes mellitus with Nephropathy (Neph) complications compared with 20 control group with average age (13-67) years.. The results sh

Background: Cytokines have long been implicated in the pathogenesis of autoimmune diabetes in a number of studies, and playing a role in the initiation of β-cell damaging process. The objective of this study is to gain more understanding about the role of cytokines in initiation of T1DM, through assessment of IFN-γ, IL-10 and IL-6 in diabetic patients.
Patients and methods: A total of 60 patients who were newly diagnosed as having T1DM (diagnosed less than five months) were included in the present study. Fifty apparently healthy control subjects were underwent the measurement of serum IFN-γ, IL-10 and IL-6 by ELISA.
Results: Higher serum levels of IFN-γ, IL-10, and Il-6 were observed in the investigated

     The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels , additionally, glucagon-like peptide-1 delays gastric emptying and suppresses appetite. The impaired secretion of glucagon-like peptide-1 has negative influence on hyperlipidemia, diabetes  and insulin resistance related diseases the levels of its secretion change with the intake of different nutrients. Some drugs also have influence on GLP-1 secretion .

Objective: Atorvastatin therapy is now recommended for reduction of cardiovascular risk in type 2 diabetic patients (T2DM), based on convincing evidence of reductions in mortality and vascular events in major clinical outcome trials. The aim is to evaluate the effects of atorvastatin on proinflammatory markers (TNF-α, IL-6), HbA1c andleptin in obese patients with type 2 diabetes. Methods: Sixty fivenewly diagnosed T2DM patients were randomly allocated into 2 groups; group I treated with metformin only; in group II atorvastatin was added with metformin. Twenty healthy subjects were enrolled as control group. While maintaining their usual eating habits, fasting blood samples were collected at baseline and after 12 weeks of treatment. Results

  L-Phenylalanine amino acid was condensed with 2-hydroxybezaldehyde to give the Schiff base sodium 2-(2-hydroxybenzylideneamino)-3-phenylpropanoate, which was used as a precursor [NaHL]. The precursor was reacted with 1,2-dichloroethane to give the Schiff base sodium 2,2'-(2,2'-(ethane-1,2diylbis(oxy))bis(2,1-phenylene))bis(methan-1-yl-1-ylidene)bis(azan1-yl-1-ylidene)bis(3-phenyl propanoate), which was used as a ligand [Na2L], in complexation with some metal (II) chloride MCl2, where [M= Co(II), Ni(II), Cu(II) and Zn(II)], to give [M(L)] complexes. The [Na2L] ligand and All complexes were characterized by spectroscopic methods, [FTIR, UV-Vis, atomic absorption], melting point, chloride content, conductivity and magnetic susceptibi

         Serum adenosine deaminase (ADA) activity was determined in 30 blood sample of type 1 diabetic individuals 30 blood sample for the type 2 and 15 normal children as a control for type 1 15 normal adults as control for type 2. The mean ADA activity and specific activity in type 1 was (8.85± 5.55 U/mg of protein) which is compared with control (32.11± 1.54 U/mg of protein) while in type 2 was (48.46±11.91 U/mg of protein) is compared with control (5.18± 2.27 U/mg of protein ). We conclude that the altered blood level of ADA activity may help in predicting immunological dysfunction in diabetic individuals and also has a prognostic value.

Abstract

 Background: Diabetes mellitus is the most common endocrine illness, affecting an increasing number of people all over the world. It is caused by a lack, or inadequate synthesis of insulin by the pancreas leading to an increase in blood glucose concentrations. Type 2 diabetes mellitus is the most strongly linked disease to obesity of all disorders. The number of obesity-related diabetes is predicted to reach 300 million by 2025. The term 'diabesity' was coined as a result of this strong link, therefore, weight loss is seen as a key therapeutic goal in the prevention and management of type 2 diabetes mellitus. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agon

Background: Coronary artery disease (CAD) is a major contributor to morbidity and mortality worldwide. Early-onset CAD, also known as PCAD, is a severe form of CAD associated with high mortality and a poor prognosis. Early diagnosis is crucial to reducing complications. While hsCRP is an established biomarker for CAD, kalirin is a potential novel biomarker due to its role in promoting smooth muscle proliferation and endothelial dysfunction. Objective: To evaluate the relationship between serum kalirin and hsCRP levels with the presence and severity of PCAD and to compare the diagnostic value of both biomarkers. Method: The study recruited 92 participants into two groups: the PCAD group (46) included patients with confirmed CAD by an